Dan G. Duda, DMD, Ph.D., of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at ...

For decades, the go-to treatments for cancer have been chemotherapy, radiation and surgery — but some experts are calling ...

Tina Willits, now 53, thought she had just two years to live. Today, she is cancer-free — and she wants the world to know about the treatment that saved her.

As the founder and CEO of Immunocine Cancer Center, based in Cancún, Mexico, he has transformed his vision into reality with ...

AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...

CAN-2409 resulted in disease-free survival improvements for patients with high-risk, localized prostate cancer.

Candel Therapeutics' experimental immunotherapy for prostate cancer significantly improved the time patients lived before their disease returned, helping the company's shares more than double in value ...

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in ...

The immunotherapy, CAN-2409, in combination with radiation therapy, helped 75.2% patients live without any sign of the cancer after 54 months of treatment, the company said on Wednesday.

AstraZeneca’s Imfinzi (durvalumab) has been approved in the USA for the treatment of adults with limited-stage small cell ...

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital ...

AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...